Inhibitors | Comment | Organism | Structure |
---|---|---|---|
galidesivir | - |
Severe acute respiratory syndrome coronavirus 2 |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
nucleoside triphosphate + RNAn | Severe acute respiratory syndrome coronavirus 2 | - |
diphosphate + RNAn+1 | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Severe acute respiratory syndrome coronavirus 2 | P0DTD1 | replicase polyprotein 1ab; SARS-CoV-2 | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
nucleoside triphosphate + RNAn | - |
Severe acute respiratory syndrome coronavirus 2 | diphosphate + RNAn+1 | - |
? |
Synonyms | Comment | Organism |
---|---|---|
RDRP | - |
Severe acute respiratory syndrome coronavirus 2 |
RNA-dependent RNA polymerase | - |
Severe acute respiratory syndrome coronavirus 2 |
General Information | Comment | Organism |
---|---|---|
drug target | analysis of the enzyme as a potential therapeutic drug target using a computational approach. Targeting the RdRpactive sites, ASP760 and ASP761, by antiviral drugs could be a potential therapeutic option for inhibition of coronavirus RdRp, and thus viral replication. Target-based virtual screening and molecular docking results show that the antiviral Galidesivir and its structurally similar compounds show promise against SARS-CoV-2. CID123624208 and CID11687749 may be considered for in vitro and in vivo clinical trials | Severe acute respiratory syndrome coronavirus 2 |